Ginkgo Bioworks Holdings, Inc. Class A Common Stock (DNA)
7.7600
-0.1100 (-1.40%)
NYSE · Last Trade: May 11th, 1:08 AM EDT
Detailed Quote
Previous Close
7.870
Open
7.970
Bid
7.540
Ask
8.010
Day's Range
7.620 - 8.070
52 Week Range
5.000 - 38.58
Volume
1,026,326
Market Cap
-
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
1,298,659
Chart
About Ginkgo Bioworks Holdings, Inc. Class A Common Stock (DNA)
Ginkgo Bioworks is a biotechnology company that focuses on the design and engineering of microbial strains for various applications across diverse industries, including pharmaceuticals, agriculture, and industrial biotechnology. By leveraging advanced genetic engineering and synthetic biology techniques, Ginkgo aims to create custom organisms that can produce valuable ingredients, enhance agricultural yields, or contribute to sustainable manufacturing processes. The company operates through a platform model, allowing collaborations with partners to transform biological systems into efficient and scalable solutions that address real-world challenges, all while paving the way for a future with more sustainable and tailored biological products. Read More
Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that the companies have entered into an updated collaboration renegotiated from a prior contract signed in 2022.
Ginkgo Bioworks introduces a protein large language model and API, developed with Google Cloud, to streamline drug discovery by leveraging AI and proprietary biological data, offering affordable and accessible tools for researchers.
Ginkgo Bioworks Holdings Inc (NYSE:DNA) shares are surging Tuesday after the company announced the launch of its new protein large language model (LLM) built on Google Cloud.
DNA stock results show that Ginkgo Bioworks Holdings missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
